Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and M

BMS gets an important win for Opdivo combination in kidney c...

BMS eyes August FDA verdict for Opdivo/Yervoy in first-line ...

BMS builds case for long-term use of Opdivo in kidney cancer

Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, showing that more than a quarter of patients were alive after fiv

BMS' Opdivo/Yervoy combo hits a snag in adjuvant melanoma

FDA decision on Opdivo/Yervoy in liver cancer due next March